Rezolute Inc. (RZLT)
2.75
0.11 (4.17%)
At close: Apr 17, 2025, 3:59 PM
2.75
0.00%
After-hours: Apr 17, 2025, 04:05 PM EDT
4.17% (1D)
| Bid | 2.5 |
| Market Cap | 166.47M |
| Revenue (ttm) | 58K |
| Net Income (ttm) | -71.13M |
| EPS (ttm) | -1.23 |
| PE Ratio (ttm) | -2.24 |
| Forward PE | -2.24 |
| Analyst | Buy |
| Ask | 3.05 |
| Volume | 907,037 |
| Avg. Volume (20D) | 620,635 |
| Open | 2.81 |
| Previous Close | 2.64 |
| Day's Range | 2.63 - 2.81 |
| 52-Week Range | 2.21 - 6.19 |
| Beta | 0.97 |
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrei...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 14, 2013
Employees 64
Stock Exchange NASDAQ
Ticker Symbol RZLT
Website https://www.rezolutebio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for RZLT stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 372.73% from the latest price.
Stock Forecasts7 months ago
+22.07%
Rezolute shares are trading higher after the compa...
Unlock content with
Pro Subscription
10 months ago
-23.45%
Rezolute shares are trading lower after the company announced a proposed public offering of common stock and pre-funded warrants.
